ArticleUpdates in surgery2026
Efficacy and safety of adjuvant targeted therapy plus immunotherapy in hepatocellular carcinoma patients with high-risk recurrence factors after hepatectomy.
Article in Updates in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) has postoperative recurrence rates reaching 70% at five years in high-risk patients. Despite advances in surgical technique, effective adjuvant strategies for patients undergoing radical hepatectomy remain limited. This study aimed to evaluate adjuvant tyrosine kinase inhibitors (TKIs) plus immune checkpoint inhibitors (ICIs) in HCC patients with high-risk recurrence factors after hepatectomy. We retrospectively analyzed 312 HCC patients with high-risk factors who underwent radical hepatectomy between January 2019 and December 2023. Patients were divided into an adjuvant group (n = 68) receiving TKIs plus ICIs and a control group (n = 244). Propensity score matching at a 1:2 ratio was applied. The primary endpoint was recurrence-free survival (RFS). After matching, 156 patients were included (52 adjuvant, 104 control). The median RFS was 31.8 months in the adjuvant group versus 17.2 months in the control group (P = 0.003). Adjuvant therapy was an independent protective factor for RFS (HR = 0.61, 95% CI 0.41-0.91, P = 0.014) and overall survival (HR = 0.70, 95% CI 0.52-0.95, P = 0.023). Patients with multiple tumors, maximum tumor diameter > 5 cm, microvascular invasion, and portal vein tumor thrombus showed potential differential RFS benefit. Grade ≥ 3 adverse events totaled 11 events (16%), with no grade 4 or 5 events. Postoperative adjuvant TKI plus ICI therapy significantly prolonged RFS with acceptable safety in HCC patients with high-risk recurrence factors.
Indexed as
Identifiers
42806231What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.